Open AccessNGP 555, a γ‐secretase modulator, lowers the amyloid biomarker, Aβ 42, in cerebrospinal fluid while preventing Alzheimer's disease cognitive decline in rodents
Author(s) -
Kounnas Maria Z.,
LaneDonovan Courtney,
Nowakowski Dan W.,
Herz Joachim,
Comer William T.
Publication year - 2017
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1016/j.trci.2016.09.003
Subject(s) - amyloid (mycology) , biomarker , disease , cognitive decline , gamma secretase , cerebrospinal fluid , medicine , cognition , alzheimer's disease neuroimaging initiative , amyloid precursor protein secretase , amyloid β , cognitive impairment , alzheimer's disease , amyloid precursor protein , pharmacology , neuroscience , dementia , psychology , chemistry , pathology , biochemistry
Alzheimer's disease (AD) is defined by the progressive accumulation of amyloid plaques and neurofibrillary tangles in the brain which precedes cognitive decline by years. Methods Using amyloid biomarkers, chemical modeling, mouse behavioral models, and drug development techniques, we investigate the properties of NGP 555, a clinical‐stage γ‐secretase modulator. Results NGP 555 shifts amyloid peptide production to the smaller, nonaggregating forms of amyloid. Our preclinical studies show beneficial effects on amyloid biomarkers, pathology, and cognition. NGP 555 has successfully completed chemistry, pharmacology, toxicity, metabolism, and safety studies. Discussion Abundant data support Aβ 42 as a target for prophylactic or early‐stage intervention therapies in AD. The γ‐secretase modulator, NGP 555 is being actively developed in human clinical trials for the prevention of Alzheimer's disease with the overall aim to achieve an appropriate balance of potency/efficacy on reducing the toxic forms of amyloid versus safety.